CervoMed's Neflamapimod Reports Phase 2b Results In DLB Patients, Showed Significant Improvements On Primary And Key Secondary Outcomes Measure; Phase 3 Trial Set for H2 2026

Phase 2b trial showed significant improvements on primary and key secondary outcomes measures, most prominently in patients without AD co-pathology

Significant reduction in key neurodegeneration biomarker correlated with treatment response, suggesting neflamapimod may act on underlying disease

CervoMed preparing to initiate Phase 3 registrational trial in patients with DLB

in the second half of 2026

BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Today in a late-breaking oral session at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference in San Diego, California, clinical investigators shared the full results of the Phase 2b RewinD-LB trial of neflamapimod, being developed by CervoMed Inc. (NASDAQ:CRVO) for the treatment of dementia with Lewy bodies (DLB). In the trial, neflamapimod, which targets the neuroinflammation and synaptic dysfunction that are known to drive DLB disease progression, demonstrated a significant and clinically meaningful effect on multiple outcomes in DLB patients, including on the primary outcome measure, change in CDR sum-of-boxes (CDR-SB). These positive clinical outcomes were correlated with observed reductions in glial fibrillary acidic protein (GFAP), a biomarker of neuronal damage, supporting neflamapimod's mode of action targeting the underlying mechanism of DLB.